IPO registrations (S-1, F-1) · Registrants
CymaBay Therapeutics, Inc.
- SEC CIK
- 1042074 · filings on EDGAR ↗
- Former names
- METABOLEX, INC. (2009–2009); METABOLEX INC (2002–2009)
- Registration
- Form S-1, first filed 2013-11-29, last 2014-07-17; 2 initial registrations, 2 amendments
- Outcome
- Final prospectus filed 2014-07-22; declared effective 2013-12-24
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 7575 GATEWAY BOULEVARD, SUITE 110, Newark, CA 94560
- EIN
- 94-3103561
- EDGAR entity type
- operating
- Insiders and CEO pay
- CymaBay Therapeutics, Inc. on the corporate pages
Offering terms
- Final price
- $6.13 per share (424B4 filed 2014-07-22)
- Shares sold
- 4,000,000
- Gross proceeds
- $24,520,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CBAY
- Lead underwriters
- Cowen; Stifel
- Syndicate
- Roth Capital Partners; National Securities Corporation
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: CYMABAY THERAPEUTICS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: CYMABAY THERAPEUTICS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: CymaBay Therapeutics, Inc. Fuzzy (name and state)
- Business registration: CymaBay Therapeutics, Inc. Fuzzy (name and state)
- Business registration: CYMABAY THERAPEUTICS, INC. Fuzzy (name and state)
- Business registration: CYMABAY THERAPEUTICS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: CYMABAY THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: CymaBay Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: CymaBay Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 10
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-11-29 | S-1 | S-1 (registration) | CymaBay Therapeutics, Inc. | 0001193125-13-458134 ↗ |
| 2013-12-20 | S-1/A | S-1/A (amendment) | CymaBay Therapeutics, Inc. | 0001193125-13-481095 ↗ |
| 2013-12-24 | EFFECT | EFFECT (declared effective) | CymaBay Therapeutics, Inc. | 9999999995-13-003671 ↗ |
| 2014-04-08 | S-1 | S-1 (registration) | CymaBay Therapeutics, Inc. | 0001193125-14-135542 ↗ |
| 2014-07-17 | S-1/A | S-1/A (amendment) | CymaBay Therapeutics, Inc. | 0001193125-14-270970 ↗ |
| 2014-07-21 | S-1MEF | S-1MEF (added securities) | CymaBay Therapeutics, Inc. | 0001193125-14-274625 ↗ |
| 2014-07-21 | EFFECT | EFFECT (declared effective) | CymaBay Therapeutics, Inc. | 9999999995-14-002177 ↗ |
| 2014-07-22 | 424B4 | 424B4 (final prospectus) | CymaBay Therapeutics, Inc. | 0001193125-14-275614 ↗ |
| 2014-11-25 | EFFECT | EFFECT (declared effective) | CymaBay Therapeutics, Inc. | 9999999995-14-003512 ↗ |
| 2015-01-20 | EFFECT | EFFECT (declared effective) | CymaBay Therapeutics, Inc. | 9999999995-15-000140 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-07-17 | S-1/A | registration statement | 3,500,000 | - | Nasdaq CBAY | 4 | primary document; shares headline, cover names 4 | document ↗ | ||
| 2014-07-22 | 424B4 | final prospectus | $6.13 | 4,000,000 | $24,520,000 | Nasdaq CBAY | 4 | primary document; price line, shares headline, proceeds computed, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG | TenPercentOwner | 1 | 2013 | ||
| ALTA BIOPHARMA PARTNERS III LP | TenPercentOwner | 1 | 2013 | ||
| ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC | TenPercentOwner | 1 | 2013 | ||
| GOLDFISCHER CARL | Director | 15 | 2013–2019 | ||
| Kumar Hari | Director | 6 | 2013–2015 | ||
| LANGE LOUIS G | Director | 7 | 2013–2015 | ||
| McWherter Charles | Officer | Chief Science Officer; Chief Scientific Officer; President of R&D; Sr. Vice President; SVP & Chief Scientific Officer | 30 | 2013–2024 | |
| PENHOET EDWARD | Director | 5 | 2013–2015 | ||
| Shah Sujal | Director,Officer; Officer | Chief Executive Officer; Chief Financial Officer; Interim CEO; Interim President & CEO; President & CEO | 33 | 2013–2024 | |
| Van Wart Harold | Director,Officer | President and CEO | 10 | 2013–2017 | |
| Versant Affiliates Fund II-A, LP | TenPercentOwner | 1 | 2013 | ||
| Versant Side Fund II, LP | TenPercentOwner | 1 | 2013 | ||
| Versant Venture Capital II, LP | TenPercentOwner | 1 | 2013 | ||
| von Emster Kurt | Director | 13 | 2013–2020 | ||
| Boudes Pol F | Officer | Chief Medical Officer | 9 | 2014–2019 | |
| Wills Robert James | Director | 17 | 2015–2024 | ||
| Martin Robert L. | Officer | Sr. Vice President; SVP, Nonclinical & Manuf. | 6 | 2015–2018 | |
| Rosemark Kirk | Officer | V.P. Regulatory & Quality | 6 | 2015–2017 | |
| OMara Patrick J. | Officer | SVP, Business Development; VP, Business Development | 7 | 2016–2018 | |
| STEIN EVAN A. | Director | 8 | 2016–2019 | ||
| TRUEX PAUL F | Director | 9 | 2016–2021 | ||
| Weiland Robert J. | Director | 7 | 2016–2019 | ||
| Booth Robert F. | Director | 6 | 2016–2019 | ||
| Loewy Caroline M | Director | 12 | 2016–2024 | ||
| Menold Daniel | Officer | Vice President, Finance | 16 | 2017–2024 | |
| Dickinson Klara | Officer | Chief Regulatory Officer; See Remarks; SVP, Regulatory Affairs & QA; SVP, Regulatory and Quality | 11 | 2017–2024 | |
| EMSTER KURT VON | Director | 30 | 2017–2024 | ||
| Quinlan Paul T | Officer | General Counsel | 20 | 2017–2024 | |
| Dorling Janet | Director; Officer | Chief Commercial Officer | 12 | 2019–2024 | |
| Aghazadeh Behzad | TenPercentOwner | 4 | 2020–2023 | ||
| Avoro Capital Advisors LLC | TenPercentOwner | 4 | 2020–2023 | ||
| WIGGANS THOMAS G | Director | 6 | 2021–2024 | ||
| STUART LEWIS J | Officer | Chief Commercial Officer | 4 | 2021–2023 | |
| KIM DENNIS D | Officer | Chief Medical Officer | 7 | 2021–2023 | |
| Lefebvre Eric | Director | 5 | 2022–2024 | ||
| Shantharam Harish | Officer | Chief Financial Officer | 4 | 2023–2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2015-08-14 | CymaBay Therapeutics, Inc. | Biotechnology | $324,999 | $324,999 | 2 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | CymaBay Therapeutics, Inc. | CA | State business registries | name and state |
| Business registration | CymaBay Therapeutics, Inc. | CA | State business registries | name and state |
| Business registration | CYMABAY THERAPEUTICS, INC. | CA | State business registries | EIN (EXACT, as the state registration reports it) |
| Business registration | CYMABAY THERAPEUTICS, INC. | CA | State business registries | EIN (EXACT, as the state registration reports it) |
| Business registration | CYMABAY THERAPEUTICS, INC. | CA | State business registries | name and state |
| Business registration | CYMABAY THERAPEUTICS, INC. | CA | State business registries | name and state |
| Form D issuer | CymaBay Therapeutics, Inc. | CA | Form D private offerings | CIK (EXACT) |
| Patent assignee | CymaBay Therapeutics, Inc. | CA | Patents (USPTO) | name and state |
| SEC filer | CymaBay Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | CymaBay Therapeutics, Inc. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | CYMABAY THERAPEUTICS, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CA first:
- CONNETICS CORP CA
- SIBIA NEUROSCIENCES INC CA
- MEDIVATION, INC. CA
- IMMUSOL INC CA
- DYNAVAX TECHNOLOGIES CORP CA
- RIGEL PHARMACEUTICALS INC CA
- Diadexus, Inc. CA
- CRESCENDO PHARMACEUTICALS CORP CA
- SPIROS DEVELOPMENT CORP II INC CA
- BIOMARIN PHARMACEUTICAL INC CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health